Jing Li

US Patent:

7022720, Apr 4, 2006

Filed:

Aug 23, 2002

Appl. No.:

10/227509

Inventors:

Patrick G. Harran - Dallas TX, US
Jing Li - Dallas TX, US
Susan Jeong - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61P 35/00
A61K 31/42
A61K 31/425
C07D 487/00

US Classification:

514366, 514375, 540457

Abstract:

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.

US Patent:

7202246, Apr 10, 2007

Filed:

Jun 8, 2005

Appl. No.:

11/147520

Inventors:

Zhenkun Ma - Dallas TX, US
In Ho Kim - Lewisville TX, US
Jing Li - Dallas TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 225/04
A61K 31/495
A61P 31/04

US Classification:

514250, 540453, 540457

Abstract:

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

US Patent:

7226931, Jun 5, 2007

Filed:

Jul 21, 2005

Appl. No.:

11/186425

Inventors:

Charles Z. Ding - Plano TX, US
Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
Susan Harran - Dallas TX, US
Yong He - Arlington TX, US
Keith P. Minor - Dallas TX, US
In Ho Kim - Lewisville TX, US
Jamie C. Longgood - Carrollton TX, US
Yafei Jin - Dallas TX, US
Keith D. Combrink - Fort Worth TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 498/08
A61K 31/4709
A61P 31/04

US Classification:

514306, 540458, 548138, 548208

Abstract:

Rifamycin derivatives having the following structure of general formula I (both hydroquinone and corresponding quinone (C-C) forms):.

US Patent:

7229996, Jun 12, 2007

Filed:

Jul 21, 2005

Appl. No.:

11/186187

Inventors:

Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
Susan Harran - Dallas TX, US
Yong He - Arlington TX, US
Keith P. Minor - Dallas TX, US
In Ho Kim - Lewisville TX, US
Charles Z. Ding - Plano TX, US
Jamie C. Longgood - Carrolton TX, US
Yafei Jin - Dallas TX, US
Keith D. Combrink - Fort Worth TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 498/08
A61K 31/4709
A61P 31/04

US Classification:

51425217, 514278, 514306, 540459

Abstract:

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C-C) forms):.

US Patent:

7238694, Jul 3, 2007

Filed:

Jan 12, 2005

Appl. No.:

11/034279

Inventors:

Charles Z. Ding - Plano TX, US
Yafei Jin - Dallas TX, US
Jamie C. Longgood - Carrollton TX, US
Zhenkun Ma - Dallas TX, US
Jing Li - Dallas TX, US
In Ho Kim - Flower Mound TX, US
Keith P. Minor - Dallas TX, US
Susan Harran - Dallas TX, US

Assignee:

Cumbre Pharmaceuticals, Inc. - Dallas TX

International Classification:

C07D 498/08
C07D 519/00
A61K 31/4709
A61K 31/496
A61P 31/04

US Classification:

51425304, 51425308, 514312, 540456

Abstract:

The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

US Patent:

7247634, Jul 24, 2007

Filed:

Jan 12, 2005

Appl. No.:

11/034195

Inventors:

Zhenkun Ma - Dallas TX, US
Yafei Jin - Dallas TX, US
Jing Li - Dallas TX, US
Charles Z. Ding - Plano TX, US
Keith P. Minor - Dallas TX, US
Jamie C. Longgood - Carrollton TX, US
In Ho Kim - Flower Mound TX, US
Susan Harran - Dallas TX, US
Keith Combrink - Fort Worth TX, US
Timothy W. Morris - Coppell TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 498/08
A61K 31/395
A61P 31/04

US Classification:

51425304, 51425308, 514278, 514300, 514312, 540456

Abstract:

Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

US Patent:

7256187, Aug 14, 2007

Filed:

Mar 9, 2005

Appl. No.:

11/076172

Inventors:

Jing Li - Dallas TX, US
Charles Z. Ding - Plano TX, US
Zhenkun Ma - Dallas TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 498/18
C07D 513/18
A61K 31/535
A61K 31/395
A61P 31/04

US Classification:

5142328, 51425301, 51425305, 51425308, 51425402, 51425411, 514300, 514321, 514339, 540456

Abstract:

The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position.

US Patent:

7265107, Sep 4, 2007

Filed:

Mar 9, 2005

Appl. No.:

11/076173

Inventors:

Jing Li - Dallas TX, US
Zhenkun Ma - Dallas TX, US

Assignee:

Cumbre Pharmaceuticals Inc. - Dallas TX

International Classification:

C07D 498/18
A61K 31/395
A61K 31/535
A61P 31/04

US Classification:

5142295, 51425308, 514277, 540456

Abstract:

The current invention relates to a series of rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the 3,4-cyclo-rifamycin derivatives having an oxime group at the C-11 position.